|The Medicines Company to Present New Data from TANGO II Study of VABOMERE™ (meropenem and vaborbactam) at IDWeek 2017|
–VABOMERE was associated with higher overall cure and lower mortality versus “best available therapy” in subjects with known or suspected carbapenem-resistant Enterobacteriaceae (CRE)–
–VABOMERE was also associated with better safety and significantly better overall risk-benefit than best available therapy–
In the TANGO II study, VABOMERE was associated with a higher clinical cure versus “best available therapy” (BAT) in patients with a baseline organism that was carbapenem-resistant Enterobacteriaceae (mCRE-MITT population) at both end-of-therapy (EOT) (VABOMERE 64.3% vs. BAT 33.3%; p=0.04) and test-of-cure (TOC) (VABOMERE 57.1% vs. BAT 26.7%; p=0.04). In immunocompromised patients, VABOMERE was also associated with a higher clinical cure versus BAT at EOT (VABOMERE 60% vs. BAT 12.5%; p<0.01), as well as lower mortality.
VABOMERE was associated, across all patients, with decreased nephrotoxicity and fewer treatment-related adverse events versus BAT. An analyses using the composite endpoints of clinical failure or nephrotoxicity demonstrated a risk-benefit profile favoring VABOMERE versus BAT (32.1% VABOMERE vs 80.0% BAT (95% CI: −74.5 to −21.2; P< 0.001)).
In July 2017, randomization in the TANGO II study was stopped early, following a recommendation by the TANGO II Independent Data Safety Monitoring Board (DSMB), based on an analysis of 72 patients, including 43 patients with microbiologically evaluable carbapenem-resistant Enterobacteriaceae (CRE) infections of blood, lung, urinary tract and abdominal organs. The DSMB recommended, based on risk-benefit considerations, that randomization of additional patients to the best available therapy comparator arm should not continue.
VABOMERE was recently approved by the
“We are excited that the TANGO II data affirm our intention to continue
the development of VABOMERE to address serious infections due to
Klebsiella pneumoniae carbapenemase (KPC)-producing CRE,” said
A total of nine posters on VABOMERE, including comprehensive analyses
from the TANGO II study, are now available to IDWeek registrants
and will be presented on Friday, October 6th and Saturday,
October 7th. The electronic versions of posters can be
accessed on The
Summaries of the key findings from poster presentations, as detailed in the IDWeek 2017 schedule, are as follows:
1862: Clinical Outcomes of Serious Infections due to Carbapenem-Resistant Enterobacteriaceae (CRE) in TANGO II, a Phase 3, Randomized, Multi-National, Open-Label Trial of Meropenem-Vaborbactam (M-V) vs. Best Available Therapy (BAT) - VABOMERE monotherapy was associated with a higher rate of clinical cure compared to BAT at both EOT and TOC across all infection types in the mCRE-MITT population. At EOT, clinical cure was 64.3% for VABOMERE versus 33.3% for BAT (p=0.04). At TOC, clinical cure was 57.1% for VABOMERE versus 26.7% for BAT (p=0.04).
VABOMERE was associated with fewer treatment-related adverse events (AEs) versus BAT (VABOMERE 24.4% vs. BAT 44.0%) and decreased nephrotoxicity as evidenced by serum creatinine increase ≥0.5 mg/dL (VABOMERE 11.1% vs. BAT 24.0%). An exploratory analyses using the composite endpoints of clinical failure or nephrotoxicity demonstrated a risk-benefit profile favoring VABOMERE versus BAT (32.1% VABOMERE vs 80.0% BAT (95% CI: −74.5 to −21.2; p < 0.001)).
1867: Meropenem-Vaborbactam vs. Best Available Therapy for Carbapenem-Resistant Enterobacteriaceae Infections in TANGO II: Primary Outcomes by Site of Infection – At EOT/TOC, VABOMERE showed clinical cure of 50% to 58% vs. 25% to 37.5% with BAT in mCRE-MITT patients with bacteremia. Mortality at 28 days in the pooled patient population with bacteremia, hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) was 25% for VABOMERE vs. 44% for BAT (43.7% reduction). In patients with complicated urinary tract infections/acute pyelonephritis (cUTI/AP), the overall success at EOT was 72.7% for VABOMERE compared to 50% for BAT; success at TOC was 42.9% vs. 50% for VABOMERE and BAT, respectively.
1868: Meropenem-Vaborbactam vs. Best Available Therapy for Carbapenem-Resistant Enterobacteriaceae Infections in TANGO II: Outcomes in Immunocompromised Patients - Approximately 40% of patients with CRE in TANGO II were immunocompromised (n=18). Treatment of these immunocompromised CRE patients with VABOMERE was associated with higher clinical cure rate (60% vs. 12.5%; P=0.01) and lower mortality (20% vs. 37%) than BAT. Among immunocompromised subjects, when compared to BAT, VABOMERE was associated with fewer AEs (84.6% vs. 100%), drug-related AEs (30.8% vs. 40.0%), serious AEs (38.5% vs. 50.0%), discontinuations of study drug or study due to AEs (15.4% vs. 30.0%) and renal-related AEs (7.7% vs. 40.0%).
Poster 1874: Assessment of MIC Increases with Meropenem-Vaborbactam and Ceftazidime-Avibactam in TANGO II (a Phase 3 Study of the Treatment of CRE Infections). The objective of this study was to examine the minimum inhibitory concentration (MIC) increases with meropenem-vaborbactam and ceftazidime-avibactam in patients with KPC-producing CRE enrolled in the TANGO II trial that were treated with these agents. One patient treated with VABOMERE had a fourfold change in MIC detected in a post-treatment bacterial isolate; this change remained in the susceptible range for VABOMERE (MIC ≤ 4 ug/ml). One of four patients treated with ceftazidime-avibactam monotherapy as BAT had a 256-fold change in MIC that became resistant to ceftazidime-avibactam (MIC > 128 ug/ml), with mutations in the KPC enzyme similar to those recently reported by other investigators.
Poster 1835: Meropenem-Vaborbactam Pharmacokinetics in Subjects with Chronic Renal Impairment, Including Hemodialysis. Meropenem and vaborbactam pharmacokinetics were determined following a single dose to subjects with varying degrees of renal impairment, including patients undergoing hemodialysis. The changes in the pharmacokinetics of meropenem and vaborbactam were similar for patients with mild to severe renal impairment, with the relationship between drug clearance and estimated glomerular filtration rate (eGFR) for meropenem and vaborbactam were similar, allowing for dosage reduction in renal impairment having a similar proportional reduction for each component. Hemodialysis removes both meropenem and vaborbactam from plasma, and thus a maintenance dose of VABOMERE is required after a dialysis session.
Poster 1852: Meropenem-Vaborbactam Pharmacokinetic-Pharmacodynamic
(PK-PD) Target Attainment Analyses as Support for Dose Selection in
Patients with Normal Renal Function and Varying Degrees of Renal
Impairment. Dosage regimens of VABOMERE in
Poster 1879: Meropenem-Vaborbactam: Outcomes in Subjects with Renal Impairment in Phase 3 Studies TANGO I and II. The efficacy of some recently approved beta-lactamase inhibitor combinations has been noted to decrease in patients with moderate renal impairment. This poster examined safety and efficacy in subsets of patients with renal impairment treated with VABOMERE in the TANGO I and TANGO II studies. In TANGO I and II, 11.5% and 20.9% of patients had a baseline creatinine clearance of less than 50 ml/min, respectively. In TANGO I, overall success in patients with creatinine clearance < 50 ml/min at the end of IV treatment was 100% in VABOMERE treated patients compared to 90.9% for piperacillin-tazobactam; these values in patients with a creatinine clearance > 50 ml/min were 98.2% vs. 94.3% for VABOMERE and piperacillin/tazobactam, respectively. In TANGO II, the clinical cure at EOT in patients in the mCRE-mMITT population with renal impairment (creatinine clearance < 50 ml/min) was 40% vs. 25% for VABOMERE and piperacillin/tazobactam, respectively.
Poster 1234: Activity of Meropenem-Vaborbactam
Against Enterobacteriaceae Isolates Carrying bla-KPC Collected Worldwide.
Over 34,000 clinical isolates of Enterobacteriaceae collected
during 2014-2016 from the worldwide SENTRY surveillance were tested for
susceptibility to VABOMERE. KPC- producing isolates were detected in 17
countries and the incidence ranged from 0.1% to 11.3% of all
Enterobacteriaceae, depending on the country. Meropenem-vaborbactam
inhibited 98.6% of isolates at
Poster 1866: Meropenem-Vaborbactam (VABOMERE) vs. Piperacillin-Tazobactam in TANGO I (a Phase 3, Randomized, Double-blind Trial): Outcomes by Baseline MIC in Adults with cUTI or AP. This poster examined the relation between MIC to VABOMERE or piperacillin/tazobactam to determine if the MIC or non-susceptibility to piperacillin/tazobactam was associated with clinical cure or microbial eradication in TANGO-1. Microbial eradication at end of intravenous treatment (EOIVT) in patients treated with piperacillin/tazobactam who had a non-susceptible Enterobacteriaceae at baseline was 26/30 (86.7%) vs. 116/124 (93.5%) in those with a susceptible organism (P>0.1). There was no relation between piperacillin/tazobactam or VABOMERE MIC and clinical cure of microbial eradication.
VABOMERE™ (meropenem and vaborbactam) is indicated for the treatment of patients 18 years of age and older with complicated urinary tract infections (cUTI), including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae species complex.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of VABOMERE and other antibacterial drugs, VABOMERE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
IMPORTANT SAFETY INFORMATION
VABOMERE is contraindicated in patients with known hypersensitivity to any components of VABOMERE (meropenem and vaborbactam), or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactam antibacterial drugs.
Warnings and Precautions
The most frequently reported adverse reactions occurring in ≥3% of patients treated with VABOMERE were headache, phlebitis/infusion site reactions, and diarrhea.
Please see www.vabomere.com for the full prescribing information.
About TANGO II
TANGO II is a multi-center, randomized, open-label Phase III clinical trial of VABOMERE versus “best available therapy” in patients with serious infections (cUTI, bacteremia, HABP/VABP, and complicated intraabdominal infections) suspected or documented to be caused by CRE. Patients with CRE were randomized to receive either VABOMERE monotherapy or the “best available therapy” for up to 14 days. Patients randomized to the best available therapy arm of the trial were given antimicrobial therapy often consisting of two to four drugs used in combination; this treatment was selected for each patient by the investigator based on available clinical laboratory and other patient data, and thus represents the current standard of care used for the treatment of CRE infections.
About Carbapenem-Resistant Enterobacteriaceae (CRE)
Enterobacteriaceae comprise a family of gram-negative bacteria that
includes Klebsiella sp., E. coli, Enterobacter sp. and others. This
group of bacteria collectively are largely responsible for
hospital-acquired infections due to gram-negative bacteria.
Enterobacteriaceae have become increasingly resistant to the widely used
beta-lactam class of antibiotics due to production of enzymes known as
beta-lactamases that degrade these antibiotics. The worldwide
dissemination of newer beta-lactamases known as carbapenemases has been
responsible for resistance to the carbapenem and other classes of
Patients at risk for CRE infections include those with prior
colonization, the institutionalized elderly, immunocompromised patients,
mechanically ventilated patients, use of prior antibiotics, and those
with multiple underlying comorbidities. Infections due to CRE are
associated with high antibiotic failure rates, high mortality (up to
50%), and high cost to hospitals, third party payers, and society (which
could range from
Due to the paucity of antibiotics with activity against CRE pathogens, clinicians are often forced to treat CRE infections, such as cUTIs, with combinations of antibiotics that had been sparingly used over the past two decades.
In light of the poor outcomes associated with CRE infections and the critical role of carbapenem antibiotics for treatment of resistant gram negative infections, CRE is considered an urgent antimicrobial resistance threat by the United States CDC, and the WHO recently designated development of new drugs for CRE to be a critical priority.
About The Infectious Disease Business
The Medicines Company Infectious Disease Business (MDCO IDC) is
committed to bringing life-saving antimicrobial products to patients
with the most serious drug-resistant infections – infections caused by
“super bugs” which are no longer treatable with available antibiotics.
MDCO IDC encompasses basic research and drug discovery focused on
bacterial mechanisms of drug resistance; drug development focused on the
most threatening bacterial diseases; and a distribution and commercial
infrastructure that serves the leading hospitals and healthcare
In addition to the development and approval of VABOMERE, MDCO IDC has,
since 2014, successfully received approval for and launched two
antibiotics against serious infections: ORBACTIV® (oritavancin)
for the treatment of acute bacterial skin and skin-structure infections
in adults, caused by designated pathogens, including
methicillin-resistant Staphylococcus aureus, and a new formulation of
MINOCIN® (minocycline) for Injection, which is among the few
Statements contained in this press release that are not purely
historical may be deemed to be forward-looking statements for purposes
of the safe harbor provisions under The Private Securities Litigation
Reform Act of 1995. Without limiting the foregoing, the words
"believes," "anticipates," "expects," “potential,” and similar
expressions are intended to identify forward-looking statements. These
forward-looking statements involve known and unknown risks and
uncertainties that may cause the Company's actual results, levels of
activity, performance or achievements to be materially different from
those expressed or implied by these forward-looking statements.
Important factors that may cause or contribute to such differences
include whether clinical trials will advance on a timely basis, or at
all, or succeed in achieving their specified endpoints; whether
physicians, patients and other key decision makers will accept clinical
trial results; whether the Company will make regulatory submissions on a
timely basis, or at all; whether the Company’s regulatory submissions
will receive approvals from regulatory agencies on a timely basis, or at
all; and such other factors as are set forth in the risk factors
detailed from time to time in the Company's periodic reports and
registration statements filed with the